Logo

American Heart Association

  44
  0


Final ID: MP2193

Prevalence of atrial fibrillation increases major adverse cardiovascular events, particularly heart failure hospitalization, in patients with peripheral arterial disease

Abstract Body (Do not enter title and authors here): Background: Peripheral arterial disease (PAD) is a leading cause of atherosclerotic disease mortality, with prevalence estimated to be 11% in the US. Studies have found that major adverse cardiovascular events (MACE) are increased in PAD patients, particularly in the presence of atherosclerotic cardiac diseases. However, whether cardiac arrhythmic diseases such as atrial fibrillation (AF) also increase this risk is unknown. We sought to determine, in a PAD population, whether the presence of AF, compared to its absence, increases the risk of MACE (all-cause death, myocardial infarction, hospitalization for heart failure [HF], stroke, and hospitalization for unstable angina).
Methods: The Intermountain Health data from Jan 2006 to Dec 2021 was used to identify adult patients with a first-time PAD diagnosis and having a second visit within 18-months (n=7613; 98.8% with symptomatic PAD). Outcomes were examined using multivariable Cox proportional hazard regressions.
Results: A total of 1723 (22.6%) PAD patients had prior AF. The table shows differences in demographic and clinical PAD patients with and without AF. Approximately 25% of PAD patients with AF had a MACE within 1-year and 46% within 3-years compared to 12% and 25%, respectively, for those without AF. Death and HF hospitalization were the two greatest contributors to MACE. After adjustment for baseline differences and guideline-directed medical therapy (GDMT), those with AF were 21% more likely to have MACE and were 1.4-1.5 times more likely to be hospitalized for HF compared to those without AF.
Conclusions: AF was prevalent, found in a quarter of patients with PAD. The rate of MACE events was double when AF was present. After adjustment for other factors, AF patients had a 21% increased risk of MACE. HF hospitalization was a major contributor to this risk. AF should be assessed for in PAD patients and aggressive preventative treatment for MACE implemented.
  • Le, Viet  ( Intermountain Medical Center , Salt Lake Cty , Utah , United States )
  • Bair, Tami  ( Intermountain Medical Center , Salt Lake Cty , Utah , United States )
  • May, Heidi  ( INTERMOUNTAIN MEDICAL CENTER , Salt Lake City , Utah , United States )
  • Bride, Daniel  ( Intermountain Healthcare , Murray , Utah , United States )
  • Anderson, Jeffrey  ( Intermountain Medical Center , Salt Lake Cty , Utah , United States )
  • Muhlestein, Joseph  ( Intermountain Medical Center , Salt Lake Cty , Utah , United States )
  • Knowlton, Kirk  ( Intermountain Medical Center , Salt Lake Cty , Utah , United States )
  • Packer, Douglas  ( Intermountain Medical Center , Salt Lake Cty , Utah , United States )
  • Knight, Stacey  ( Intermountain Medical Center , Salt Lake Cty , Utah , United States )
  • Author Disclosures:
    Viet Le: DO have relevant financial relationships ; Researcher:Janssen/J&J:Active (exists now) ; Advisor:Pfizer:Active (exists now) ; Advisor:Amgen:Active (exists now) ; Advisor:Bayer:Active (exists now) ; Advisor:Novartis:Active (exists now) ; Advisor:Idorsia:Active (exists now) ; Advisor:Lexicon:Active (exists now) ; Research Funding (PI or named investigator):Kardia:Active (exists now) | Tami Bair: DO NOT have relevant financial relationships | Heidi May: DO NOT have relevant financial relationships | Daniel Bride: No Answer | Jeffrey Anderson: DO NOT have relevant financial relationships | Joseph Muhlestein: DO NOT have relevant financial relationships | Kirk Knowlton: DO have relevant financial relationships ; Research Funding (PI or named investigator):novartis:Active (exists now) | Douglas Packer: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):COI will be uploaded to my account:Active (exists now) | Stacey Knight: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

AI and Biomarker-Driven Approaches to Atrial Fibrillation and Stroke Risk Stratification

Monday, 11/10/2025 , 12:15PM - 01:15PM

Moderated Digital Poster Session

More abstracts on this topic:
A Multimodality Education Model Improves Healthcare Professionals' Competency in Managing Cardiovascular Risk Factors in Type 2 Diabetes: A Mixed-Methods Study

Madhusudhan Divya, Pressley Alyssa, El Sayed Nuha, Okeke Oge, Bradley Sarah, Blanco Caroline, Perla Esteban, Jennings Ruby, Picou Kylie, Mcweeny Patrick, Crabill Carrianne

Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings From the ATTRibute-CM Study

Alexander Kevin, Bhatt Kunal, Judge Daniel, Grodin Justin, Akinboboye Olakunle, Chen Chris, Tamby Jean-francois, Castano Adam, Fox Jonathan, Fontana Marianna, Gillmore Julian, Sarswat Nitasha, Grogan Martha, Solomon Scott, Davis Margot, Cuddy Sarah, Kittleson Michelle, Shah Keyur, Griffin Jan, Ruberg Frederick, Khouri Michel

More abstracts from these authors:
You have to be authorized to contact abstract author. Please, Login
Not Available